FREMONT, Calif., July 28, 2026
Alamar Biosciences, Inc. has announced the commercial launch of the NULISAseq™ Immune 340 Panel, its most comprehensive multiplex immune proteomics platform designed to advance translational research, biomarker discovery, and drug development. The new panel significantly expands the company’s immune profiling capabilities by enabling the simultaneous measurement of approximately 340 immune-related proteins from a single biological sample. Building upon the previously introduced NULISAseq™ Inflammation Panel 250, the Immune 340 Panel provides researchers with unprecedented sensitivity to detect low-abundance immune biomarkers, including checkpoint inhibitors, cytokines, chemokines, metabolic regulators, and cell death pathway proteins that are often undetectable using conventional immunoassays. The technology is expected to accelerate scientific discoveries across cancer, cardiovascular disease, metabolic disorders, autoimmune diseases, and aging research, while supporting pharmaceutical companies in identifying novel biomarkers, improving patient stratification, and advancing precision medicine. The launch reinforces Alamar Biosciences’ growing leadership in precision proteomics, delivering highly sensitive analytical tools capable of revealing early biological signals associated with disease progression and therapeutic response.
Advanced Immune Proteomics Enhances Biomarker Discovery
The NULISAseq™ Immune 340 Panel has been developed to overcome one of the biggest challenges in immunology research—the accurate detection of extremely low-concentration proteins involved in immune regulation. Traditional immunoassays often fail to detect biomarkers circulating at femtogram-per-milliliter (fg/mL) or sub-picogram-per-milliliter levels, limiting researchers’ ability to study early immune responses and disease mechanisms. Alamar’s new multiplex platform addresses this limitation by simultaneously profiling hundreds of immune proteins, providing a far more comprehensive view of immune system activity from a single sample. The expanded panel includes both well-established inflammatory biomarkers and difficult-to-measure regulatory proteins associated with immune checkpoints, apoptosis, cytokine signaling, chemokine activity, and cellular metabolism. By capturing these complex biological interactions in a single assay, researchers gain a deeper understanding of immune pathway crosstalk, feedback mechanisms, and disease biology, ultimately supporting more effective biomarker discovery and translational research across multiple therapeutic areas.
Supports Precision Medicine Across Multiple Disease Areas
The launch of the Immune 340 Panel is expected to significantly enhance research into diseases where immune dysfunction plays a central role, including oncology, cardiovascular disease, metabolic disorders, autoimmune diseases, and age-related conditions. Researchers increasingly recognize that disease progression is driven by complex networks of interacting proteins rather than individual biomarkers, making comprehensive immune profiling essential for identifying clinically meaningful biological signatures. The platform is particularly valuable for studying inflammaging, the chronic low-grade inflammation associated with aging that contributes to increased risk of cardiovascular disease, neurodegenerative disorders, metabolic disease, and cancer. By enabling ultra-sensitive detection of previously inaccessible immune mediators, the technology provides pharmaceutical researchers with new opportunities to investigate mechanisms of disease, identify predictive biomarkers, monitor treatment responses, and improve patient stratification during clinical development. Industry experts also believe the platform’s combination of broad multiplexing and exceptional analytical sensitivity will accelerate the development of targeted therapeutics and companion diagnostic strategies within precision medicine programs.
Advertisement
Expanding Precision Proteomics for Drug Development
The NULISAseq™ Immune 340 Panel further strengthens Alamar Biosciences’ precision proteomics portfolio, which combines the company’s proprietary NULISA™ technology with the high-performance ARGO™ HT System to deliver ultra-sensitive protein detection across a broad dynamic range. The integrated platform enables highly automated, high-specificity protein analysis while maintaining flexible multiplexing capabilities that support large-scale translational and clinical research studies. By providing comprehensive immune proteome analysis from minimal sample volumes, the technology helps pharmaceutical companies and academic researchers generate richer biological insights that may accelerate therapeutic development and improve clinical decision-making. As demand continues to grow for highly sensitive proteomic technologies capable of supporting next-generation biomarker research, Alamar Biosciences is positioning its latest innovation as an important tool for advancing precision medicine, enabling earlier disease detection, improving understanding of complex immune biology, and supporting the discovery of more effective therapies across some of the world’s most challenging diseases.
Source: Alamar Biosciences press release
